SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.
SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.
SCYNEXIS, Inc. entered into an Award/Contract with BARDA to support development of SCY-247, its second-generation fungerp antifungal candidate. BARDA’s potential total non-dilutive funding is up to $214 million. The initial base period commences in September 2026 and provides approximately $18.5 million to advance oral and intravenous SCY-247 into a Phase 2 study in patients with invasive candidiasis. The remaining potential award is subject to BARDA exercising up to six options, which could extend the contract for up to ten years.
If all options are exercised, the contract could fund SCY-247 development through New Drug Application submissions for treatment of invasive candidiasis and prevention of invasive fungal infections in high-risk patients. It is a cost-share arrangement: BARDA supports eligible direct and general and administrative expenses, while SCYNEXIS expects to fund its share of near-term program costs within its existing operating plan. The company said its previously communicated SCY-770 development plans and projected cash runway into 2029 remain unchanged.
SCYNEXIS INC (SCYX) reported that director Steven Keith Burke received new equity awards on September 18, 2026. He was granted 5,750 restricted stock units, each convertible into one share of common stock as they vest, and 5,750 stock options to buy common shares at an exercise price of $4.46 per share, expiring on September 18, 2036. One third of the RSUs will vest each year on the grant-date anniversary starting September 18, 2027, and the options vest one third on the first anniversary of the grant date, with the remaining two thirds vesting in equal monthly installments over the following 24 months, in each case contingent on his continued service. Following these awards he holds 5,750 common shares directly, plus 5,750 stock options, and no Rule 10b5-1 trading plan is reported.
SCYNEXIS INC (SCYX) disclosed that Steven Keith Burke has become a reporting person by filing an initial statement of beneficial ownership of securities as a director. The filing does not report any current holdings of SCYNEXIS securities or any recent transactions in the company’s securities.
SCYNEXIS, Inc. (SCYX) announced that its Board appointed Steven K. Burke, M.D. as a director effective September 18, 2026, with his term running until the 2027 annual meeting, and named him to the Board’s Nominating and Corporate Governance Committee.
As a non-employee director, Dr. Burke will receive annual cash retainers and initial equity awards, including stock options and restricted stock units with multi‑year vesting schedules. The company highlights his more than 30 years of biopharmaceutical experience and nephrology-focused drug development background to support the advancement of SCY-770, its orphan-designated AMPK activator being developed for Autosomal Dominant Polycystic Kidney Disease.
SCYNEXIS INC (SCYX) reported that its Chief Financial Officer, Sanjay Subramanian, received a grant of stock options on September 9, 2026 to purchase 100,000 shares of common stock at an exercise price of $4.91 per share. These options expire on September 8, 2036 and vest 25% after one year, with the remainder vesting in equal monthly installments over the following 36 months, contingent on continued service.
SCYNEXIS INC (SCYX) reported that Sanjay Subramanian, the company’s Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. The filing does not list any reportable transactions or equity holdings in SCYNEXIS common stock or derivatives as of the reporting date.
SCYNEXIS, Inc. (SCYX) reported a planned transition in its finance leadership, with longtime Chief Financial Officer Ivor Macleod retiring and ceasing to serve as CFO, principal financial officer and principal accounting officer effective September 9, 2026, while remaining through October 9, 2026 to support a smooth transition. The company appointed Sanjay Subramanian as its new Chief Financial Officer effective September 9, 2026, also designating him as principal financial officer and principal accounting officer under an employment agreement.
Subramanian’s package includes a $500,000 annual base salary, a $20,000 sign-on bonus, and an annual performance bonus opportunity of up to 40% of base salary, plus a stock option for 100,000 shares of SCYNEXIS common stock at a $4.91 per-share exercise price vesting over four years. The agreement provides severance protections, including salary continuation, equity vesting acceleration, and COBRA benefits for nine months, or 18 months in connection with certain terminations within 12 months after a change of control.
SCYNEXIS, Inc. received an amended Schedule 13G from CVI Investments, Inc. and Heights Capital Management, Inc., reporting beneficial ownership of SCYNEXIS common stock. The Reporting Persons collectively report beneficial ownership of 615,522 Shares, representing 5.9% of the outstanding common stock as of June 30, 2026.
The position consists of 150,551 Shares of common stock and additional Shares issuable upon exercise of warrants, which are subject to 4.99% and 9.99% beneficial ownership limitations. Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and may exercise shared voting and dispositive power over these Shares, while both entities disclaim beneficial ownership beyond their pecuniary interest.
Great Point Partners, LLC, together with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, reports beneficial ownership of 4,076,068 shares of SCYNEXIS, Inc. common stock, representing 9.99% of the class based on 9,930,329 shares outstanding after a 1-for-8 stock split effective June 1, 2026.
The position is held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd., including common shares and warrant shares limited by a 9.99% Beneficial Ownership Cap on warrant exercises. Great Point acts as investment manager to the funds; Dr. Jay and Ms. Nordahl may be deemed beneficial owners but each disclaims ownership except to the extent of pecuniary interest.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 1,041,824 shares of SCYNEXIS, Inc. common stock, including 498,346 shares issuable upon exercise of warrants. This position represents 9.99% of the outstanding common stock, based on approximately 9,930,329 shares outstanding after giving effect to a one-for-eight reverse stock split effective May 29, 2026.
All 1,041,824 shares are reported with shared voting and dispositive power and no sole voting or dispositive power. The shares are directly held by Adage Capital Partners, L.P., with Adage Capital Management, L.P. as investment manager and Messrs. Atchinson and Gross reporting through their roles in affiliated entities.